STOCK TITAN
  1. Home
  2. News
  3. AVIR

Atea Pharmaceuticals Inc - AVIR STOCK NEWS

IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results
earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021
conferences earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis
clinical trial covid-19
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
management
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors
management
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021
conferences earnings
Stock AVIR logo
Atea Pharmaceuticals Inc

Nasdaq:AVIR

AVIR Rankings

#4159 Ranked by Market Cap
#4631 Ranked by Stock Gains
N/A Ranked by Dividends

AVIR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.